A detailed history of First Foundation Advisors transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, First Foundation Advisors holds 3,270 shares of BMY stock, worth $132,271. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,270
Previous 2,722 20.13%
Holding current value
$132,271
Previous $139,000 27.34%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$47.98 - $54.4 $26,293 - $29,811
548 Added 20.13%
3,270 $177,000
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $220,341 - $262,928
-4,545 Reduced 62.54%
2,722 $139,000
Q3 2023

Nov 15, 2023

SELL
$57.89 - $64.73 $40,001 - $44,728
-691 Reduced 8.68%
7,267 $421,000
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $4,714 - $5,234
-74 Reduced 0.92%
7,958 $508,000
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $9,659 - $10,955
-147 Reduced 1.8%
8,032 $556,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $12,874 - $15,244
-188 Reduced 2.25%
8,179 $588,000
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $246 - $145,688
-1,896 Reduced 18.47%
8,367 $595,000
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $54,465 - $59,985
750 Added 7.88%
10,263 $790,000
Q1 2022

May 05, 2022

BUY
$61.48 - $73.72 $61,787 - $74,088
1,005 Added 11.81%
9,513 $695,000
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $217,576 - $253,643
-4,057 Reduced 32.29%
8,508 $530,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $36,507 - $42,764
617 Added 5.16%
12,565 $743,000
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $34,855 - $37,957
563 Added 4.95%
11,948 $798,000
Q1 2021

May 18, 2021

SELL
$59.34 - $66.74 $350,165 - $393,832
-5,901 Reduced 34.14%
11,385 $719,000
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $18,014 - $20,414
312 Added 1.84%
17,286 $1.07 Million
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $482,412 - $534,576
8,400 Added 97.97%
16,974 $1.02 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $474,741 - $555,019
-8,660 Reduced 50.25%
8,574 $504,000
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $532,718 - $774,163
11,481 Added 199.57%
17,234 $961,000
Q4 2019

Feb 11, 2020

BUY
$49.21 - $64.19 $51,375 - $67,014
1,044 Added 22.17%
5,753 $369,000
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $201,403 - $238,793
4,709 New
4,709 $239,000
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $261,830 - $289,527
-5,868 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$45.12 - $53.8 $36,186 - $43,147
802 Added 15.83%
5,868 $280,000
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $285,636 - $370,401
-5,858 Reduced 53.63%
5,066 $263,000
Q3 2018

Nov 13, 2018

BUY
$55.19 - $62.25 $7,450 - $8,403
135 Added 1.25%
10,924 $678,000
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $56,997 - $71,041
1,128 Added 11.68%
10,789 $597,000
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $1.3 Million - $1.5 Million
-21,708 Reduced 69.2%
9,661 $611,000
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $53,166 - $57,965
887 Added 2.91%
31,369 $1.92 Million
Q3 2017

Nov 14, 2017

SELL
$55.23 - $63.74 $977,902 - $1.13 Million
-17,706 Reduced 36.74%
30,482 $1.94 Million
Q2 2017

Aug 14, 2017

BUY
N/A
48,188
48,188 $2.69 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $86B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track First Foundation Advisors Portfolio

Follow First Foundation Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Foundation Advisors, based on Form 13F filings with the SEC.

News

Stay updated on First Foundation Advisors with notifications on news.